You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Kowa

Showing 1 - 25 of 105
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Age Related Cataracts, Pseudoexfoliation Syndrome Trial (Phakoemulsification, Ziemer Z8 Femtolaser, Kowa Avansee Preset)

Not yet recruiting
  • Age Related Cataracts
  • Pseudoexfoliation Syndrome
  • Phakoemulsification
  • +2 more
  • (no location specified)
Sep 22, 2023

Tumor Malignant Trial in Kashiwa-Shi, Nagoya-Shi, Sunto-Gun (SAR408701, dexamethasone, naphazoline)

Completed
  • Neoplasm Malignant
  • Kashiwa-Shi, Japan
  • +2 more
Jan 6, 2023

T2DM (Type 2 Diabetes), Metformin, SGLT2-Inhibitors Trial in Matsumoto (Tofogliflozin, Metformin)

Recruiting
  • T2DM (Type 2 Diabetes Mellitus)
  • +2 more
  • Matsumoto, Nagano, Japan
    Shinshu University
Jul 21, 2022

Non-alcoholic Fatty Liver Disease Trial in Kanazawa (Tofogliflozin, Glimepiride)

Completed
  • Non-alcoholic Fatty Liver Disease
  • Kanazawa, Ishikawa, Japan
    Kanazawa University Graduate School of Medical Sciences
Jun 30, 2021

Secondary Cataract Surgery, Aphakia, Complicated Cataract Surgery Trial in Linz (IOL Master 700, Casia-2, MS-39)

Recruiting
  • Secondary Cataract Surgery
  • +2 more
  • IOL Master 700
  • +6 more
  • Linz, Upper Austria, Austria
  • +1 more
Jun 12, 2023

Hyperlipidemia, HIV Trial in New York (Pitavastatin, Darunavir, Ritonavir)

Completed
Has Results
  • Hyperlipidemia
  • HIV
  • New York, New York
    Bellevue/NYU AIDS Clinical Trials Unit
Jul 22, 2020

Fuchs Endothelial Corneal Dystrophy Trial (Ripasudil, Placebo)

Not yet recruiting
  • Fuchs Endothelial Corneal Dystrophy
  • (no location specified)
Apr 21, 2023

Hypercholesterolemia Trial in Japan (K-877 0.2 mg/day (once daily), K-877 0.4 mg/day (once daily), Placebo (once daily))

Recruiting
  • Hypercholesterolemia
  • K-877 0.2 mg/day (once daily)
  • +2 more
  • Aichi, Japan
  • +14 more
Jun 20, 2023

Fuchs Endothelial Corneal Dystrophy Trial in Kansas City, Portland (Ripasudil, Placebo)

Recruiting
  • Fuchs Endothelial Corneal Dystrophy
  • Kansas City, Missouri
  • +1 more
Apr 5, 2023

Lens Luxation, IOL Subluxation, IOL Opacification Trial in Vienna (Pars plana vitrectomy, IOL explantation, Scleral IOL fixation

Recruiting
  • Lens Luxation
  • +3 more
  • Pars plana vitrectomy
  • +3 more
  • Vienna, Austria
    Medical University of Vienna
Oct 20, 2023

NASH Trial in United States (K-877-ER, CSG452, Placebo)

Recruiting
  • NASH
  • Homewood, Alabama
  • +31 more
Dec 1, 2022

Healthy Trial (K-001, K-877-ER, CSG452)

Not yet recruiting
  • Healthy
  • (no location specified)
Feb 1, 2023

Fuchs' Endothelial Corneal Dystrophy Trial in Worldwide (K-321 Solution, Placebo Solution)

Completed
  • Fuchs' Endothelial Corneal Dystrophy
  • K-321 Solution
  • Placebo Solution
  • Los Angeles, California
  • +28 more
Sep 20, 2022

Dry Eye Disease Trial in Lakeway (K-161, Placebo)

Recruiting
  • Dry Eye Disease
  • Birmingham, Alabama
  • +50 more
Jan 17, 2023

Dyslipidemias Trial in Japan (K-877 ER 0.2 mg/day morning administration (once daily), K-877 ER 0.2 mg/day evening

Completed
  • Dyslipidemias
  • K-877 ER 0.2 mg/day morning administration (once daily)
  • K-877 ER 0.2 mg/day evening administration (once daily)
  • Fukuoka, Japan
  • +13 more
Aug 8, 2022

Covid19 Trial in Japan, Thailand (K-237 0.3-0.4mg/kg (once daily), Placebo 0.3-0.4mg/kg (once daily))

Active, not recruiting
  • Covid19
  • K-237 0.3-0.4mg/kg (once daily)
  • Placebo 0.3-0.4mg/kg (once daily)
  • Aichi, Japan
  • +54 more
Aug 7, 2022

Acute Pain Trial in Pasadena (K-285, Menthol)

Terminated
  • Acute Pain
  • Pasadena, California
    Lotus Clinical Research, LLC
Mar 11, 2022

Peripapillary Atrophy to Diagnose Glaucoma in High Myopia

Not yet recruiting
  • Myopia
  • +4 more
  • OCT imaging
  • Guangzhou, Guangdong, China
    Zhongshan Ophthalmic Center, Sun Yat-sen University
Jul 27, 2023

Dyslipidemia Trial in United States (K-877-ER (Dose A), K-877-ER (Dose B), K-877-IR)

Completed
  • Dyslipidemia
  • K-877-ER (Dose A)
  • +2 more
  • Anniston, Alabama
  • +11 more
Dec 1, 2021

Dyslipidemias Trial in Kanagawa, Osaka, Tokyo (K-877 ER 0.2 mg/day (once daily), K-877 ER 0.4 mg/day (once daily), K-877 IR 0.2

Completed
  • Dyslipidemias
  • K-877 ER 0.2 mg/day (once daily)
  • +2 more
  • Kanagawa, Japan
  • +10 more
Dec 2, 2021

Hyperlipidemia Trial in China (K-877 0.1 mg tablet, Fenofibrate 200 mg capsule, Placebo tablet)

Recruiting
  • Hyperlipidemia
  • K-877 0.1 mg tablet
  • +3 more
  • Anhui, China
  • +32 more
Dec 8, 2021

Hypercholesterolemia Trial in Japan (K-924 LD, K-924 HD)

Completed
  • Hypercholesterolemia
  • K-924 LD
  • K-924 HD
  • Aichi, Japan
  • +12 more
Sep 5, 2021

Aqueous Flare in Rhegmatogenous Retinal Detachments Treated With

Completed
  • Retinal Detachment
  • Aqueous flare measurement
  • Nancy, Grand EST, France
    BERROD Jean-Paul MD
Sep 14, 2021

Healthy Volunteers Trial in Austin (Pitavastatin (NK-104), Lopinavir/ritonavir)

Completed
Has Results
  • Healthy Volunteers
  • Austin, Texas
    (unnamed)
Jun 9, 2021

Healthy Trial in Austin (K-877)

Completed
  • Healthy
  • Austin, Texas
    PPD Development, LP
Aug 5, 2021